JP2025513022A5 - - Google Patents

Info

Publication number
JP2025513022A5
JP2025513022A5 JP2024559610A JP2024559610A JP2025513022A5 JP 2025513022 A5 JP2025513022 A5 JP 2025513022A5 JP 2024559610 A JP2024559610 A JP 2024559610A JP 2024559610 A JP2024559610 A JP 2024559610A JP 2025513022 A5 JP2025513022 A5 JP 2025513022A5
Authority
JP
Japan
Prior art keywords
lamp
nucleic acid
isolated nucleic
acid molecule
molecule according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024559610A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025513022A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/065588 external-priority patent/WO2023201201A1/en
Publication of JP2025513022A publication Critical patent/JP2025513022A/ja
Publication of JP2025513022A5 publication Critical patent/JP2025513022A5/ja
Pending legal-status Critical Current

Links

JP2024559610A 2022-04-10 2023-04-10 免疫応答増強遺伝子を含むバイシストロニックlamp構築物およびその使用方法 Pending JP2025513022A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263329463P 2022-04-10 2022-04-10
US63/329,463 2022-04-10
PCT/US2023/065588 WO2023201201A1 (en) 2022-04-10 2023-04-10 Bicistronic lamp constructs comprising immune response enhancing genes and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2025513022A JP2025513022A (ja) 2025-04-22
JP2025513022A5 true JP2025513022A5 (cg-RX-API-DMAC7.html) 2026-03-31

Family

ID=86330166

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024559610A Pending JP2025513022A (ja) 2022-04-10 2023-04-10 免疫応答増強遺伝子を含むバイシストロニックlamp構築物およびその使用方法

Country Status (8)

Country Link
US (1) US20250352639A1 (cg-RX-API-DMAC7.html)
EP (1) EP4508071A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025513022A (cg-RX-API-DMAC7.html)
KR (1) KR20250004728A (cg-RX-API-DMAC7.html)
CN (1) CN119233982A (cg-RX-API-DMAC7.html)
AU (1) AU2023254186B2 (cg-RX-API-DMAC7.html)
CA (1) CA3247515A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023201201A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119798414B (zh) * 2024-12-31 2026-05-08 西安巨子生物基因技术股份有限公司 重组人xxiii型胶原蛋白、其生产方法及用途
CN121930357A (zh) * 2025-12-08 2026-04-28 北京大学第三医院(北京大学第三临床医学院) 靶向杀伤cms2型结肠癌细胞的蛋白回路及其相关生物材料与应用
CN121896287A (zh) * 2026-02-03 2026-04-21 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) 一种携带稳定遗传标记的猪细小病毒全长感染性克隆的构建方法与应用

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4237115A (en) 1977-11-23 1980-12-02 Bactex, Inc. Method of immunization against enterotoxogenic infection by Escherichia coli
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4397844A (en) 1978-02-24 1983-08-09 Ciba-Geigy Corporation Antigen derivatives and processes for their preparation
US4681762A (en) 1979-05-23 1987-07-21 Research Corporation Genetically attenuated bacterial vaccines with multiple mutations of the same phenotype
US4714681A (en) 1981-07-01 1987-12-22 The Board Of Reagents, The University Of Texas System Cancer Center Quadroma cells and trioma cells and methods for the production of same
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4593002A (en) 1982-01-11 1986-06-03 Salk Institute Biotechnology/Industrial Associates, Inc. Viruses with recombinant surface proteins
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4592002A (en) 1983-12-13 1986-05-27 Honeywell Inc. Method of digital temperature compensation and a digital data handling system utilizing the same
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
ZA858044B (en) 1984-11-01 1987-05-27 American Home Prod Oral vaccines
FR2583429B1 (fr) 1985-06-18 1989-11-03 Transgene Sa Vecteur d'expression de l'interferon u dans les cellules de mammifere, procede pour sa mise en oeuvre et produit obtenu et composition pharmaceutique contenant l'interferon u
DE3689123T2 (de) 1985-11-01 1994-03-03 Xoma Corp Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung.
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
DE3642912A1 (de) 1986-12-16 1988-06-30 Leybold Ag Messeinrichtung fuer paramagnetische messgeraete mit einer messkammer
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4925648A (en) 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions
US5601819A (en) 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
US5744166A (en) 1989-02-25 1998-04-28 Danbiosyst Uk Limited Drug delivery compositions
EP0739904A1 (en) 1989-06-29 1996-10-30 Medarex, Inc. Bispecific reagents for aids therapy
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
US5100587A (en) 1989-11-13 1992-03-31 The United States Of America As Represented By The Department Of Energy Solid-state radioluminescent zeolite-containing composition and light sources
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DK0553244T4 (da) 1990-10-05 2005-08-01 Celldex Therapeutics Inc Målrettet immunostimulering med bispecifikke reagenser
AU8727291A (en) 1990-10-29 1992-06-11 Cetus Oncology Corporation Bispecific antibodies, method of production, and uses thereof
US5179993A (en) 1991-03-26 1993-01-19 Hughes Aircraft Company Method of fabricating anisometric metal needles and birefringent suspension thereof in dielectric fluid
EP0582595A1 (en) 1991-04-26 1994-02-16 Surface Active Limited Novel antibodies, and methods for their use
SE503225C2 (sv) 1991-10-30 1996-04-22 Leif Lindholm Konsult Ab Virus-antikroppskomplex för införing av virus i mammalieceller
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
EP1306095A3 (en) 1992-03-05 2003-06-25 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
ATE182651T1 (de) 1992-06-09 1999-08-15 Hoppe Ag Riegel und türschloss
EP0657039B1 (en) 1992-08-25 1998-12-16 MERCK PATENT GmbH Paper white pdlc system
US5747323A (en) 1992-12-31 1998-05-05 Institut National De La Sante Et De La Recherche Medicale (Inserm) Retroviral vectors comprising a VL30-derived psi region
US5633234A (en) 1993-01-22 1997-05-27 The Johns Hopkins University Lysosomal targeting of immunogens
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
FR2707091B1 (fr) 1993-06-30 1997-04-04 Cohen Haguenauer Odile Vecteur rétroviral pour le transfert et l'expression de gènes dans des cellules eucaryotes.
US5928944A (en) 1994-02-04 1999-07-27 The United States Of America As Represented By The Department Of Health And Human Services Method of adenoviral-medicated cell transfection
MX9504664A (es) 1994-03-07 1997-05-31 Dow Chemical Co Conjugados de dendrimeros bioactivos y/o dirigidos.
JPH10501963A (ja) 1994-04-15 1998-02-24 ターゲテッド ジェネティクス コーポレイション 遺伝子送達融合タンパク質
FR2719316B1 (fr) 1994-04-28 1996-05-31 Idm Nouveaux complexes d'acide nucléique et de polymère, leur procédé de préparation et leur utilisation pour la transfection de cellules.
WO1996000295A1 (en) 1994-06-27 1996-01-04 The Johns Hopkins University Targeted gene delivery system
FR2722506B1 (fr) 1994-07-13 1996-08-14 Rhone Poulenc Rorer Sa Composition contenant des acides nucleiques, preparation et utilisations
FR2727689A1 (fr) 1994-12-01 1996-06-07 Transgene Sa Nouveau procede de preparation d'un vecteur viral
US5837520A (en) 1995-03-07 1998-11-17 Canji, Inc. Method of purification of viral vectors
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
FR2737222B1 (fr) 1995-07-24 1997-10-17 Transgene Sa Nouveaux vecteurs viraux et lignee pour la therapie genique
WO1997035996A1 (en) 1996-03-25 1997-10-02 Transgene S.A. Packaging cell line based on human 293 cells
JP2000514290A (ja) 1996-07-01 2000-10-31 ローヌ―プーラン・ロレ・エス・アー 組換えアデノウイルスの製造方法
AU3739697A (en) 1996-07-09 1998-02-02 Johns Hopkins University, The Gene delivery system
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
IL130198A (en) 1996-12-13 2005-09-25 Schering Corp Methods for purifying viruses
FR2759382A1 (fr) 1997-02-10 1998-08-14 Transgene Sa Nouveaux composes et compositions les contenant utilisables pour le transfert d'au moins une substance therapeutiquement active, notamment un polynucleotide, dans une cellule cible et utilisation en therapie genique
FR2760193B1 (fr) 1997-02-28 1999-05-28 Transgene Sa Lipides et complexes de lipides cationiques et de substances actives, notamment pour la transfection de cellules
FR2763958A1 (fr) 1997-05-29 1998-12-04 Transgene Sa Produit de combinaison associant un acide nucleique a une substance desorganisant la matrice extracellulaire pour la therapie genique
JP2002506436A (ja) 1997-06-13 2002-02-26 ザ ジョンズ ホプキンス ユニバーシティー 治療用ナノスフェア
AU707186B2 (en) 1997-07-01 1999-07-01 Transgene S.A. Compositions useful for transferring therapeutically active substances into a target cell, and their use in gene therapy
ES2180258T3 (es) 1998-07-07 2003-02-01 Transgene Sa Utilizacion de pautas de lectura abierta adenovirales de e4 para mejorar la expresion de genes.
US7300774B1 (en) * 1999-12-09 2007-11-27 The Regents Of The University Of California Multimeric fusion proteins of the TNF superfamily ligands
CA2364934C (fr) 1999-02-22 2011-10-18 Transgene S.A. Procede d'obtention d'une preparation virale purifiee
CA2907384C (en) * 2013-03-15 2023-08-15 Geoffrey W. STONE Composition comprised of antigen linked to a tnf superfamily ligand
EP3612556B8 (en) 2017-04-22 2024-11-20 Immunomic Therapeutics, Inc. Improved lamp constructs
WO2018204534A1 (en) * 2017-05-02 2018-11-08 Immunomic Therapeutics, Inc. Lamp (lysosomal associated membrane protein) constructs comprising cancer antigens
KR20220083773A (ko) 2019-10-18 2022-06-20 이뮤노믹 쎄라퓨틱스, 인크. 암 항원을 포함하는 개선된 lamp 구축물

Similar Documents

Publication Publication Date Title
JP7720950B2 (ja) Il-12及びil-18へのil-15系融合
US11479605B2 (en) Homodimeric protein constructs
JP2021524247A5 (cg-RX-API-DMAC7.html)
AU4016700A (en) Multimeric forms of tnf superfamily ligands
JP5148116B2 (ja) 癌胎児性抗原融合タンパク質及びその使用
Lauterbach et al. Insufficient APC capacities of dendritic cells in gene gun-mediated DNA vaccination
JP4772674B2 (ja) ヒト上皮成長因子2/neu抗原をコードする合成遺伝子およびその用途
Gupta et al. Vaccination with a fusion protein that introduces HIV-1 gag antigen into a multitrimer CD40L construct results in enhanced CD8+ T cell responses and protection from viral challenge by vaccinia-gag
AU2023282166A1 (en) Measles Virus Encoding a Tumor Antigen
AU2002254348A1 (en) Cancer immunotherapy
Kang et al. Enhancement of DNA vaccine potency by antigen linkage to IFN‐γ‐inducible protein‐10
WO2024233390A2 (en) Anaplastic lymphoma kinase (alk) specific t cell receptors and methods of use thereof
AU2023258034A1 (en) Mutant cd24 proteins and uses thereof for prophylaxis and treatment of cancer
CN116751266A (zh) 一种广谱亨尼帕病毒保护性抗原及其应用
CN103789340A (zh) 一种高效制备重组人mica蛋白的方法
Ferrantelli et al. Extracellular vesicle-based anti-HOXB7 CD8+ T cell-specific vaccination strengthens antitumor effects induced by vaccination against Her2/neu
CN109568574A (zh) sPD1蛋白和/或sPD1基因作为免疫佐剂的应用
CN119431549B (zh) 一种LTα1β2体外表达生产方法
CN1298385C (zh) 异种血管内皮细胞生长因子疫苗及其制备方法
WO2025228249A1 (zh) 一种工程化改造gpi锚定信号肽、其融合蛋白及应用
CN121422200A (zh) 多靶点肿瘤基因疫苗及其应用
CN118649231A (zh) 靶向cDC1的肿瘤基因疫苗
JP2025170217A (ja) 可溶性多量体融合タンパク質、及び融合タンパク質を使用する治療方法
CN122011208A (zh) 一种羊口疮病毒双抗原自组装纳米颗粒疫苗及其制备和应用
CN121699950A (zh) 一种肿瘤抗原与趋化因子共编码体系及其应用